Results 111 to 120 of about 16,388 (147)

Integrative Proteomic and Lipidomic Analysis of Patients With Acute Myocardial Infarction Treated With PCSK9 Antibodies and Statins. [PDF]

Circ Genom Precis Med
Schmidt LE, Burnap SA, Singh B, Takov K, Losdat S, Schrutka L, Galli L, Theofilatos K, Otto GW, Hengstenberg C, Tzoulaki I, Lang IM, Koskinas KC, Speidl WS, Räber L, Mayr M.   +15 more
europepmc   +1 more source

Advanced therapy in familial hypercholesterolemia. [PDF]

Can Fam Physician
Gao E, Brunham LR, Goldman RD.
europepmc   +1 more source

Clinician-level variation in lipid management for secondary prevention of atherosclerotic cardiovascular disease: Opportunities for practice improvement. [PDF]

Am J Prev Cardiol
Nguyen DQ, Hwang J, Rohatgi A, Joshi PH, Khera A, Peterson ED, Navar AM.   +6 more
europepmc   +1 more source

Expanding the genotypic spectrum of PCSK1 deficiency: A novel mutation in severe neonatal diarrhea. [PDF]

JPGN Rep
Saraceno E, Faini AC, Deaglio S, Pellegrini M, Buganza R, Giuliani F, Calvo PL, Pinon M.   +7 more
europepmc   +1 more source

Advances in Beyond Statin Lipid Therapies for ASCVD Risk Reduction. [PDF]

J Atheroscler Thromb
Shimabukuro M.
europepmc   +1 more source

Impact of mRNA and protein isoforms in lipoprotein metabolism and how to modulate them. [PDF]

Curr Opin Lipidol
Martinovich KM, Cale JM, Aung-Htut MT.
europepmc   +1 more source

A narrative review of PCSK9 inhibitors: from evolocumab to novel discoveries. [PDF]

Front Pharmacol
Liu HH, Li S, Li JJ.
europepmc   +1 more source

Effectiveness of PCSK9 inhibitors versus statins in type 2 diabetes and dyslipidemia: a propensity-matched study. [PDF]

Front Endocrinol (Lausanne)
Wu JY, Lin YM, Hsu WH, Liu T, Tsai YW, Huang PY, Chuang MH, Yu T, Lai CC.   +8 more
europepmc   +1 more source

Multimodal assessment of treatment with proprotein convertase subtilisin/kexin type 9 inhibitors combined with statins for regulating coronary artery plaque regression in patients with chronic/acute coronary syndrome: A meta-analysis. [PDF]

J Int Med Res
Yuan D, Cheng T, Cao Z, Wang F, Wang Y.
europepmc   +1 more source

Correction: Reduction of Cardiovascular Risk Using Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Acute Coronary Syndrome: A Systematic Review. [PDF]

Cureus
Rabih AM, Niaj A, Raman A, Uprety M, Calero MJ, Villanueva MRB, Joshaghani N, Villa N, Badla O, Goit R, Saddik SE, Dawood SN, Mohammed L.   +12 more
europepmc   +1 more source